XML 66 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions (Details Textual)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 26, 2023
USD ($)
ft²
$ / shares
Oct. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]                
Selling, general and administrative       $ 788.2 $ 563.3 $ 1,941.2 $ 1,770.8  
Goodwill       6,807.5   6,807.5   $ 5,749.0
Forecast                
Business Acquisition [Line Items]                
Payments to Acquire Businesses, Gross, Outstanding Equity Awards     $ 983.9          
Reata Pharmaceuticals, Inc                
Business Acquisition [Line Items]                
Price per share | $ / shares $ 172.50              
Consideration transferred $ 7,193.4              
Total transaction value 6,602.9              
Selling, general and administrative 196.4              
Research and development expense asset acquired 197.0              
Operating expenses 393.4              
Inventory 1,692.0              
Operating lease liabilities 151.8              
Operating lease assets $ 122.4              
Lease term 16 years              
Operating Lease Area | ft² 327,400              
Lessee, Operating Lease, Remaining Lease Term 15 years              
Fair Value Indefinite Lived Intangible Assets Discount Rate 17.00%              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period 3 years              
Goodwill $ 1,057.3              
Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services 590.5              
Reata Pharmaceuticals, Inc | Selling, general and administrative                
Business Acquisition [Line Items]                
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed       $ 26.3   $ 26.3    
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)                
Business Acquisition [Line Items]                
Intangible assets: 3,600.0              
Reata Pharmaceuticals, Inc | In-process research and development                
Business Acquisition [Line Items]                
Intangible assets: 1,900.0              
Reata Pharmaceuticals, Inc | Priority review voucher                
Business Acquisition [Line Items]                
Intangible assets: 100.0              
Reata Pharmaceuticals, Inc | Other clinical programs                
Business Acquisition [Line Items]                
Intangible assets: $ 20.0              
Reata Pharmaceuticals, Inc | Subsequent Event                
Business Acquisition [Line Items]                
Total transaction value   $ 980.0